ÁñÁ«ÊÓƵ

This cohort study assesses the association of diltiazem with risk of serious bleeding compared with metoprolol in older adults with atrial fibrillation receiving apixaban or rivaroxaban.

This cohort study uses patient data from the Medicaid and Children’s Health Insurance Program to investigate if antipsychotic treatment of children and young adults without severe somatic illness or psychosis is associated with increased risk of death.

This cohort study assesses major ischemic and hemorrhagic outcomes in Medicare beneficiaries with atrial fibrillation who were treated with rivaroxaban compared with apixaban.

This cohort study of Tennessee Medicaid enrollees from 1999 through 2014 investigates the risk of unexpected death among children and youths aged 5 through 24 years without psychosis who are new users of antipsychotic medications compared with new users of control medications.

This pharmacoepidemiology study examines the association between oral anticoagulants (warfarin, apixaban, dabigatran, and rivaroxaban), cotherapy with proton pump inhibitors (PPIs), and upper gastrointestinal (UGI) tract bleeding in Medicare beneficiaries.

This retrospective study compared risk of death among Medicaid patients in Tennessee initiating long-acting opioid therapy for chronic noncancer pain with patients taking anticonvulsants or cyclic antidepressants.

This retrospective cohort study determines that the increased risk of death associated with methadone use outside the hospital supports recommendations that it should not be a drug of first choice for treatment of noncancer pain.